NCT00679874 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Friedrich MG, Strohm O, Schulz-Menger J, Marciniak H, Luft FC, Dietz R
Contrast media-enhanced magnetic resonance imaging visualizes myocardial changes in the course of viral myocarditis. Circulation. 1998 May 12;97(18):1802-9.
McArthur HL, Chia S
Cardiotoxicity of trastuzumab in clinical practice. N Engl J Med. 2007 Jul 5;357(1):94-5.
Nathan DM
Rosiglitazone and cardiotoxicity--weighing the evidence. N Engl J Med. 2007 Jul 5;357(1):64-6. Epub 2007 Jun 5.
Wassmuth R, Lentzsch S, Erdbruegger U, Schulz-Menger J, Doerken B, Dietz R, Friedrich MG
Subclinical cardiotoxic effects of anthracyclines as assessed by magnetic resonance imaging-a pilot study. Am Heart J. 2001 Jun;141(6):1007-13.

Characterization of the Cardiotoxic Effects of Chemotherapies With Anthracyclines and Trastuzumab for Breast Cancer by Contrast-enhanced Cardiovascular Magnetic Resonance Imaging (CMR).

Details for clinical trial NCT00679874

Clinical trial NCT00679874 - References